Credit Suisse’s GSK GSK Stock Holding History

Credit Suisse’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-428,800	Closed	-$25.2M	–	4094
2019 Q4	$25.2M	Buy	+428,800	New	+$23.9M	0.02%	903

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Credit Suisse's GSK Position: Q2 2023 in Review

Credit Suisse sold out of GSK (GSK) in Q2 2023, closing a stake of 44,808 shares — an estimated $1.59M sold.

Credit Suisse first reported a position in GSK in Q2 2013 and held it in 40 quarters. The position peaked at $78.2M in Q1 2021. 827 funds tracked by Wall St. Rank hold GSK as of Q2 2023.

Credit Suisse reported no remaining GSK position as of Q2 2023 after selling out during the quarter.
Credit Suisse sold 44,808 GSK shares in Q2 2023, an estimated $1.59M.
Credit Suisse first reported a position in GSK in Q2 2013 and held it in 40 quarters.
Credit Suisse's GSK position peaked at $78.2M in Q1 2021.
827 funds tracked by Wall St. Rank held GSK as of Q2 2023.

Based on Credit Suisse's 13F filing for Q2 2023, filed 11 Aug 2023.